Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-10-17 | Apim Therapeutics (Norway) | financing round | Norsk Innovasjonskapital III AS (Norway) Sarsia Seed (Norway) Birk Venture (Norway) Ro Invest (Norway) |
Cancer - Oncology | Fundraising | |
2012-10-16 | Genmab (Denmark) | DKK 475,200,000 | private placement | Johnson & Johnson Development Corporation (USA) | Cancer - Oncology | Private placement |
2012-10-15 | Novimmune (Switzerland) and FIGHT HLH consortium | € 6 million | grant | European Commission | Immunological diseases | Grant |
2012-10-10 | Addex Therapeutics (Switzerland) | $10.3 million | private placement | institutional investors | Mental diseases - Psychiatric diseases | Private placement |
2012-10-09 | Abgentis (UK) | £75,000 (€93 090) | fundraising | Midven Limited (UK) - undisclosed business angel | Infectious diseases | Fundraising |
2012-10-09 | AMP Therapeutics (Germany) | € 1.8 million | grant | Federal Ministry of Education and Research (BMBF) (Germany) | Infectious diseases | Grant |
2012-10-08 | Affimed Therapeutics (Germany) | € 15.5 million | series D financing round | Aeris Capital (Switzerland) - BioMedInvest (Switzerland) - LSP Life Sciences Partners (The Netherlands) - Novo Nordisk (Denmark) - Orbimed (USA) | Cancer - Oncology | Fundraising |
2012-10-02 | Addex Therapeutics (Switzerland) | CHF700,000 (€578 600) | grant | Commission for Technology and Innovation (CTI) (Switzerland) | Neurodegenerative diseases - Psychiatric diseases | Grant |
2012-10-02 | Vaximm (Switzerland - Germany) | grant | Federal Ministry of Education and Research (BMBF) (Germany) | Cancer - Oncology | Grant | |
2012-10-02 | Vaximm (Germany) | grant | BioRN cluster (Germany) | Cancer - Oncology | Grant | |
2012-10-01 | Definiens (Germany) | €10 Million | private financing round | Gilde Healthcare Partners (The Netherlands) - TVM (Germany) - Cipio (Germany - USA) - Definiens\' management | Technology - Services | Fundraising |
2012-10-01 | Antabio (France) | crowdfunding | more than 200 small investors | Infectious diseases | Fundraising | |
2012-09-25 | ExpreS2ion (Denmark) Mucosis (The Netherlands) | € 1 million | grant | European Eurostars Programme (EU) | Infectious diseases | Grant |
2012-09-21 | AB-Therapeutics, now Ability Pharmaceuticals (Spain) | € 1 million | financing round | Inveready Seed Capital(Spain) Genoma España (Spain) shareholders, business angels and private investors | Cancer - Oncology | Financing round |
2012-09-20 | AyoxxA Biosystems (Germany) | € 2.6 million | Series A financing round | Wellington Partners Venture Capital - NRW.BANK (Germany) - HTGF - High-Tech-Gründerfonds (Germany) - private investors, - Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems. | Technology - Services | Fundraising |
2012-09-19 | Wellington Partners (Germany - UK - Switzerland) | € 70 million | European Investment Fund (EIF) (EU) - LfA Foerderbank Bayern (Germany) - Austria Wirtschaftsservice GmbH (Austria) - several large family offices | Fundraising | ||
2012-09-18 | CureVac (Germany) | €80 million | series D financing round | dievini Hopp BioTech (Germany) | Cancer - Oncology - Infectious diseases | Fundraising |
2012-09-18 | Lonza (Switzerland) | € 170 million | private placement | Technology - Services | Private placement | |
2012-09-18 | Mutabilis (France) | € 4 million | grant | Infectious diseases | Grant | |
2012-09-13 | Pluristem Therapeutics | $32 million | Cardiovascular diseases - Regenerative medicine | Private placement |